Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)

A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of Pritelivir versus Foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)

Pritelivir will be provided as 100 mg film-coated tablets. Pritelivir will be administered as a loading dose of 400 mg (4 x 100 mg) as first dose followed by a maintenance dose of 100 mg once daily (qd). Foscarnet will be given as intermittent infusions at a dose of 40 mg/kg every 8 hours or 60 mg/kg every 12 hours for a minimum of one hour duration for a maximum treatment duration of 28 days.